Key terms
About ANGO
AngioDynamics, Inc. operates as a medical device company, which engages in the development, manufacturing and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It operates through the Med Tech and Med Device segments. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ANGO news
Feb 22
7:46am ET
AngioDynamics price target raised to $18 from $17 at Canaccord
Feb 16
6:20am ET
Analysts’ Top Healthcare Picks: AngioDynamics (ANGO), Corcept Therapeutics (CORT)
Feb 16
6:13am ET
AngioDynamics price target lowered to $14 from $18 at H.C. Wainwright
Feb 15
4:14pm ET
AngioDynamics sells PICC, Midline product portfolios for up to $45M in cash
Feb 13
4:26pm ET
AngioDynamics Announces Key Leadership and Board Changes
Jan 23
8:10am ET
FDA clears AngioDynamics Auryon XL Catheter to treat Peripheral Arterial Disease
Jan 23
3:07am ET
AngioDynamics’ Long-Time Director Meteny Retires
Jan 08
7:55am ET
Oppenheimer Keeps Their Hold Rating on AngioDynamics (ANGO)
Jan 08
7:25am ET
AngioDynamics price target lowered to $17 from $19 at Canaccord
Jan 08
6:26am ET
Buy Rating Maintained for AngioDynamics Amidst Strategic Restructuring and New Product Launches
Jan 08
6:24am ET
AngioDynamics price target lowered to $18 from $20 at H.C. Wainwright
Jan 05
8:05am ET
AngioDynamics down 10% at $7.00 after Q2 revenue miss, FY24 guidance cut
Jan 05
8:04am ET
AngioDynamics cuts FY24 EPS view to (42c) to (35c) from (34c) to (28c)
Jan 05
8:01am ET
AngioDynamics reports Q2 EPS (5c), consensus (7c)
Dec 08
6:25am ET
Optimistic Buy Rating for AngioDynamics Supported by Trial Advancements and Market Potential
Dec 07
8:11am ET
AngioDynamics completes enrollment in Acute Pulmonary Embolism Extraction trial
No recent news articles are available for ANGO
No recent press releases are available for ANGO
ANGO Financials
Key terms
Ad Feedback
ANGO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ANGO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range